CenterBook Partners LP Sells 41,380 Shares of Indivior PLC $INDV

CenterBook Partners LP decreased its position in shares of Indivior PLC (NASDAQ:INDV) by 37.8% in the 4th quarter, Holdings Channel reports. The fund owned 68,079 shares of the company’s stock after selling 41,380 shares during the quarter. CenterBook Partners LP’s holdings in Indivior were worth $2,443,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds also recently made changes to their positions in the company. JPMorgan Chase & Co. grew its stake in shares of Indivior by 1.7% during the 4th quarter. JPMorgan Chase & Co. now owns 211,208 shares of the company’s stock worth $7,578,000 after acquiring an additional 3,620 shares during the period. WINTON GROUP Ltd bought a new position in shares of Indivior during the 4th quarter worth $291,000. Vise Technologies Inc. bought a new position in shares of Indivior during the 4th quarter worth $256,000. Bank of New York Mellon Corp grew its stake in shares of Indivior by 100.4% during the 4th quarter. Bank of New York Mellon Corp now owns 700,272 shares of the company’s stock worth $25,126,000 after acquiring an additional 350,839 shares during the period. Finally, Natixis Advisors LLC bought a new position in shares of Indivior during the 4th quarter worth $376,000. Institutional investors own 60.33% of the company’s stock.

Analyst Upgrades and Downgrades

Several research analysts have commented on the company. Zacks Research upgraded Indivior from a “hold” rating to a “strong-buy” rating in a research note on Monday, March 16th. Weiss Ratings downgraded Indivior from a “hold (c+)” rating to a “hold (c)” rating in a research note on Wednesday, May 6th. One investment analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and one has assigned a Hold rating to the company. According to data from MarketBeat.com, Indivior presently has a consensus rating of “Buy” and a consensus target price of $39.33.

Indivior Stock Up 2.3%

NASDAQ:INDV opened at $38.26 on Wednesday. The business’s 50-day moving average price is $34.94 and its two-hundred day moving average price is $34.19. Indivior PLC has a twelve month low of $13.44 and a twelve month high of $41.00. The stock has a market cap of $4.66 billion, a P/E ratio of 19.62 and a beta of 0.88.

Indivior (NASDAQ:INDV) last released its quarterly earnings results on Tuesday, March 31st. The company reported $0.96 earnings per share for the quarter. Indivior had a negative return on equity of 219.26% and a net margin of 19.44%.The firm had revenue of $317.00 million for the quarter. On average, equities research analysts expect that Indivior PLC will post 4.05 EPS for the current fiscal year.

Indivior Profile

Indivior plc is a specialty pharmaceutical company dedicated to developing and delivering treatments for addiction and related mental health disorders. The company’s portfolio centers on therapies designed to support individuals dealing with opioid dependence, alcohol use disorder and other behavioral health challenges. Its lead products include Suboxone® (buprenorphine and naloxone) sublingual film and Sublocade® (extended-release buprenorphine) injection, both of which are approved in multiple markets to aid in opioid use disorder management.

Indivior was established in 2014 through a demerger from the pharmaceuticals division of Reckitt Benckiser Group plc, inheriting decades of research and commercial expertise in addiction medicine.